Edition:
United Kingdom

AveXis Inc (AVXS.OQ)

AVXS.OQ on NASDAQ Stock Exchange Global Select Market

98.09USD
11 Dec 2017
Change (% chg)

$-1.74 (-1.74%)
Prev Close
$99.83
Open
$100.31
Day's High
$101.33
Day's Low
$97.15
Volume
146,830
Avg. Vol
150,956
52-wk High
$108.27
52-wk Low
$44.68

Latest Key Developments (Source: Significant Developments)

Avexis posts Q3 loss per share $1.52
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Avexis Inc :Avexis reports third quarter 2017 financial and operating results.Q3 loss per share $1.52.Q3 earnings per share view $-1.54 -- Thomson Reuters I/B/E/S.Avexis Inc - cash and cash equivalents‍ $374.2 million at sept 30 2017 versus $240.4 million at dec 31, 2016​.  Full Article

Avexis Inc CFO Thomas Dee resigns
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Avexis Inc :Avexis Inc - ‍on October 14 Thomas J. Dee resigned as senior vice president, chief financial officer - SEC filing.Avexis Inc - ‍ on October 19, 2017 board of directors of co appointed Phillip B. Donenberg as company's senior vice president, chief financial officer​.  Full Article

Avexis files for potential mixed shelf offering - SEC filing
Friday, 17 Mar 2017 

Avexis Inc :Files for potential mixed shelf offering; size not disclosed - SEC filing.  Full Article

AveXis announces proposed public offering of 4,000,000 shares of common stock
Tuesday, 6 Sep 2016 

AveXis Inc : Announces proposed public offering of 4,000,000 shares of common stock . PBM Capital Investments, Llc, an existing stockholder of AveXis, intends to offer and sell 433,526 shares in proposed offering .Avexis Inc says to offer and sell 3.6 million shares of its common stock in an underwritten public offering.  Full Article

Avexis files for common stock offering by selling stockholder of upto $126.5 mln
Wednesday, 24 Aug 2016 

Avexis Inc : Files for common stock offering by the selling stockholder of upto $126.5 million - SEC filing .Says co will not receive any proceeds from sale of shares to be offered by selling stockholder.  Full Article

Avexis Q2 loss per share $0.68
Thursday, 11 Aug 2016 

Avexis : Reports second quarter 2016 financial and operating results and interim data from ongoing phase 1 trial of avxs-101 in spinal muscular atrophy type 1 . Q2 earnings per share view $-0.78 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.68.  Full Article

Avexis says Avxs-101 continued to show favorable safety profile in patients
Monday, 16 May 2016 

Avexis Presents Pulmonary Data From Ongoing Phase 1 Trial Of Avxs : Gene therapy reduced need for ventilation support,allowed patients to recover from respiratory illnesses, often lethal to sma type 1 patients . Interim analysis found that none of patients in either dosing cohort required permanent ventilation as of april 1, 2016 . Avxs-101 continued to show favorable safety profile in patients studied as of april 1 . Avxs-101 showed no new treatment-related safety or tolerability concerns .Presents Pulmonary Data From Ongoing Phase 1 Trial Of Avxs-101 in spinal muscular atrophy type 1.  Full Article

Avexis Q1 loss per share $1.24
Thursday, 12 May 2016 

Avexis Inc : Avexis reports first quarter 2016 financial and operating results . Q1 loss per share $1.24 .Q1 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.  Full Article

AveXis Inc sees IPO of 4.25 mln shares priced between $19 to $21 per share
Tuesday, 9 Feb 2016 

AveXis Inc:Sees IPO of 4.25 million shares of common stock priced to be between $19.00 and $21.00 per share - SEC Filing.  Full Article

BRIEF-Avexis posts Q3 loss per share $1.52

* Avexis reports third quarter 2017 financial and operating results